Analisi costo-efficacia di dasatinib nella prospettiva del SSN italiano

Objective: Purpose of this Italian economic analysis was to estimate the cost-effectiveness of dasatinib (100 mg/day) versus high-dose (800 mg/day) imatinib (HDI), in CP-CML patients, in the perspective of the Italian National Healthcare System (NHS).